- Trials with a EudraCT protocol (62)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
62 result(s) found for: Radioisotope Therapy.
Displaying page 1 of 4.
EudraCT Number: 2012-004328-40 | Sponsor Protocol Number: INMINDFP7-HEALTH-2011-two-stage | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO | |||||||||||||
Full Title: IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES | |||||||||||||
Medical condition: mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001539-23 | Sponsor Protocol Number: PET_ONKO | Start Date*: 2006-06-07 |
Sponsor Name:department of clinical pharmacology | ||
Full Title: Does imatinib therapy lead to an increased uptake of low molecular weight substances into solid tumor metastasis in patients with hormone refractory prostate cancer? | ||
Medical condition: patients with HRPC and bone metastases will be enrolled in the study | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-006068-99 | Sponsor Protocol Number: DuoNen2020 | Start Date*: 2021-09-20 |
Sponsor Name:Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM | ||
Full Title: Tandem therapy LutaPol/ItraPol (177Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasms, Acronym: DuoNen, 2019 / ABM / 01/00077 | ||
Medical condition: Diagnosed and confirmed histopathologically disseminated or locally unresectable, well and moderately differentiated (G1 and G2) neuroendocrine neoplasms of the gastrointestinal tract (GEP-NET) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003434-87 | Sponsor Protocol Number: CPX-MA-1201 | Start Date*: 2017-08-24 | |||||||||||
Sponsor Name:Cincinnati Children's Hospital Medical Center | |||||||||||||
Full Title: A Phase 1/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies. | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003736-13 | Sponsor Protocol Number: CCTL019B2205J | Start Date*: 2017-09-29 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia | ||
Medical condition: Paediatric patients with B-cell acute lymphoblastic leukaemia and lymphoma who are refractory, relapsed to prior treatments | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-005219-36 | Sponsor Protocol Number: B9E-MC-S378 | Start Date*: 2006-03-06 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | ||
Medical condition: Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002526-39 | Sponsor Protocol Number: 20010133 | Start Date*: 2015-07-02 |
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | ||
Full Title: A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects with Acute Leukemias Undergoing Myeloblative Therapy and Allogeneic Hematopoieti... | ||
Medical condition: Oral Mucositis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-003212-11 | Sponsor Protocol Number: ITCC-101/APAL2020D | Start Date*: 2022-02-17 | |||||||||||
Sponsor Name:Princess Máxima Center | |||||||||||||
Full Title: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML | |||||||||||||
Medical condition: Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia with a documented negative test for FLT3/ITD mutation and either: - Untreated second relapse, who are s... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) ES (Ongoing) PT (Ongoing) AT (Ongoing) SE (Ongoing) IE (Ongoing) NO (Ongoing) FR (Ongoing) CZ (Ongoing) FI (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004016-58 | Sponsor Protocol Number: WPD-201P | Start Date*: Information not available in EudraCT |
Sponsor Name:WPD Pharmaceuticals Sp. z o.o. | ||
Full Title: A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin® in Pediatric Patients with Progressive, Refractory, or Recurrent Hig... | ||
Medical condition: High Grade Gliomas | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001282-17 | Sponsor Protocol Number: E7389-G000-223 | Start Date*: 2018-03-23 |
Sponsor Name:Eisai Inc. | ||
Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S... | ||
Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-018373-38 | Sponsor Protocol Number: RG_09-071 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Birmingham | ||
Full Title: A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours | ||
Medical condition: Paediatric patients aged 1-12 years with relapsed / refractory solid tumours. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Ongoing) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001238-32 | Sponsor Protocol Number: ADVL1622 | Start Date*: 2019-09-26 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation | ||
Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ||
Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-003224-38 | Sponsor Protocol Number: D4320C00015 | Start Date*: 2007-12-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer ... | |||||||||||||
Medical condition: Hormone-refractory prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) SE (Completed) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) LV (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003696-19 | Sponsor Protocol Number: E7080-G000-230 | Start Date*: 2020-02-28 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adoles... | |||||||||||||
Medical condition: Relapsed or Refractory Osteosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) BE (Completed) IE (Completed) NL (Completed) IT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000690-23 | Sponsor Protocol Number: ADVL0612;NCI-07-C-0220 | Start Date*: 2012-02-29 | |||||||||||
Sponsor Name:National Institution of Health (NCI) | |||||||||||||
Full Title: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors | |||||||||||||
Medical condition: Paediatric solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000588-42 | Sponsor Protocol Number: APN311-304 | Start Date*: 2015-03-16 | |||||||||||
Sponsor Name:Medical University Greifswald | |||||||||||||
Full Title: PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA | |||||||||||||
Medical condition: PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001929-32 | Sponsor Protocol Number: 2014/2126 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | |||||||||||||
Medical condition: Diffuse Intrinsic Pontine Glioma and Diffuse midline glioma, K27M mutant | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) SE (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000701-11 | Sponsor Protocol Number: CA180227 | Start Date*: 2008-11-25 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer Revised Protocol 03 incorporating A... | |||||||||||||
Medical condition: castration-resistant metastatic prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IE (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed) FI (Completed) SE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004735-32 | Sponsor Protocol Number: SP001 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with castrate-resistant prostate cancer | |||||||||||||
Medical condition: metastatic castrate-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010004-28 | Sponsor Protocol Number: ACNS0331 | Start Date*: 2010-04-14 | ||||||||||||||||
Sponsor Name:COG | ||||||||||||||||||
Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas... | ||||||||||||||||||
Medical condition: Medulloblastoom standard risk | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.